B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma
Cancer Research, 2022
Scientific Publications
The landmark research of BostonGene underscores the importance of combining innovative multi-platform analytics with cutting-edge software to improve patient outcomes. Explore our scientific publications to learn more.
Tumor microenvironment heterogeneity identifies potential biomarkers of response in ER-positive breast cancers treated with palbociclib
Cancer Research, 2022
Viral transcript and tumor immune microenvironment-based transcriptomic profiling of HPV-associated head and neck cancer identifies subtypes associated with prognosis
Cancer Research, 2022
Deep immune profiling by mass cytometry revealed an association between the state of immune system before treatment and response to checkpoint inhibitor therapy in clear cell renal cell carcinoma
Cancer Research, 2022
Combinatory technologies for single sample gene expression projection onto a cohort sequenced with a different technology for personalized clinical decision-making
Cancer Research, 2022
Molecular-based tumor grade predictor for breast cancer, clear cell renal cell carcinoma, and lung adenocarcinoma
Cancer Research, 2022
Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression
Blood Cancer Discovery, 2022
A digital imaging analysis (DIA) platform for identifying tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD).
Journal of Clinical Oncology, 2022
A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.
Journal of Clinical Oncology, 2022
A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response.
Journal of Clinical Oncology, 2022
Questions
Contact us